Membrane Compound Compatibility

Chemical Compatibility Index

Thomson Filter Vials are designed for small-volume sterilization and clarification of pharmacy solutions for analytical analysis. Please search the index below to find the Filter Vial suitable to your needs.

MembranePore SizeCap ColorReferance
5-FluorouracilPTFE0.2μm3031
(18F) Fluoromisondazole, MisiomidazolePVDF0.2μm5
AcebutololPES0.2μm12
Acetylsalicylic acidPES0.2μm12
Alpha1-Proteinase Inhibitor (Human)PVDF.45μm28
AlprenololPES0.2μm12
AmiloridePES0.2μm12
Amphotericin B for Injection USPPVDF.45μm1421243236
AtenololPES0.2μm12
AzathioprinePVDF.45μm35
AzodicarbonamidePES0.2μm6
Bleomycin SulfatePTFE0.2μm3031
CaffeinePES0.2μm12
CetirizinePVDF.45μm34
ChlorothiazidePES0.2μm12
ChloramphenicolPES0.2μm12
CimetidinePES0.2μm12
CiprofloxacinPES0.2μm29
Cisplatin, Cisplatin InjectionPTFE0.2μm3031
Cyclosporine APVDF0.2μm10
CytarabinePTFE0.2μm30
DaunorubicinPTFE0.2μm23031
DE-310PES0.2μm27
DiclofenacPVDF.45μm1
EnalaprilPES0.2μm12
EthionamidePTFE0.2μm17
Factor IX Complex Heat-TreatedPVDF.45μm28
GatifloxacinPVDF.45μm22
HydrochlorothiazidePES0.2μm12
IbuprofenPVDF.45μm1
IosniazidPTFE0.2μm17
isonicotinic acidPTFE0.2μm17
KetaminePES0.2μm26
Las 35917PVDF.45μm15
LevofloxacinPVDF.45μm22
LomefloxacinPVDF.45μm22
Methyl Gag; NSC-32946PTFE0.2μm3031
MetoprololPES0.2μm12
MitomycinPTFE0.2μm3031
MorphazinamidePTFE0.2μm17
NadololPES0.2μm12
Nicotinic acidPTFE0.2μm17
PaclitaxelPVDF0.2μm7
p-Aminobenzoic acid (PABA)PVDF.45μm28
p-aminosalicylic acidPTFE0.2μm1
PefloxacinPVDF.45μm22
Pentoxifylline (PTX)PVDF0.2μm23
PhenytoinPVDF.45μm33
PyrazinamidePTFE0.2μm17
PyrimethaminePVDF.45μm20
RanitidinePES0.2μm12
RifampicinPVDF.45μm16
SabeluzolePVDF.45μm11
StreptokinasePVDF.45μm24
SulfadozinePVDF.45μm20
SulphasalazinePES0.2μm12
SulpiridePES0.2μm12
TerbutalinePES0.2μm12
Thiotepa Parenteral SterilePTFE0.2μm3031
TimololPES0.2μm12
Tobramycin Vincristine SulfatePTFE0.2μm489131819303136
Tranexamic acidPES0.2μm12
Triamcinolone AcetonidePES0.2μm25
Triazinate; NSC-139105PTFE0.2μm30
TropicamidePVDF.45μm3
Vinblastine SulfatePTFE0.2μm3031

Referance:

  1. Santini, A. O. et al. (2004). p-Aminobenzoate ion determination in pharmaceutical formulations by using a potentiometric sensor immobilized in a graphite matrix. Talanta 63:833-838.
  2. Bosanquet, A.G. (1985) Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents. Cancer Chemother. Pharmacol. 14:83-95
  3. Capello, B. et al. (2001) Solubilization of tropicamide by hydroxypropyl-[beta]-cyclodextrin and water-soluable polymers: in vitro/in vivo studies. Int. J. Pharm.213:75-81.
  4. Butler, L.D., et al (1980). Effect of inline filtration on the potency of low-dose drugs. Am. J. Hosp. Pharm. 37:935-941.
  5. Chang, C.W., et al.(2007). A robotic synthesis of [18F]fluoromisonidazole([18F]FMISO), Applied Radiation and Isotopes, In Press, Accepted Manuscript, Available online 6 February.
  6. Fagny, C., et al. (2002). Ribonucleotide reductase and thymidine phosphorylation: two potential targets of azodicarbonamide. Biochem. Pharmacol. 64: 451-456.
  7. kiesewetter, et al. (2003). Fluoro-, bromo-, iodopaclitaxel derivatives: synthesis and biological evaluation. Nuclear Medicine and Biology. 30: 11-24.
  8. Elenbaas, J.K., et al. (1985). Effect of inline filtration on tobramycin delivery. Drug Intell. Clin. Pharm. 19: 122-125.
  9. Ennis, C.E., et al. (1983) In vitro study of inline filtration of medications commonly administered to pediatric cancer patients. J. Parenter Enter.Nutr. 7: 156-158.
  10. Lallemand, et. al. (2005) A novel water-soluble cyclosporine A prodrug: Ocular tolerance and in vivo kinetics. Int.J.Pharm. 295: 7-14.
  11. Verreck, G., et al. (2005). Preparation and physicochemical characterization of biodegradable nerve guides containing the nerve growth agent sabeluzole. Biomaterials 26: 1307-1315.
  12. Flaten, G.E., et al. (2006) Drug permeability across a phospholipid vesicle based barrier. A novel approach for studying passive diffusion. European Journal of Pharmaceutical Sciences 27: 80-90.
  13. Grant, A.M.(1987). Personal communication.
  14. Huber, R.C. and Riffkin, C. (1975) Inline final filters for removing particles from amphotericin B infusions. Am.J.Hosp.Pharm. 32: 173-176.
  15. Toro, I. et al. (2004). Development and validation of a capillary electrophoresis method with ultraviolet detection for the determination of the related substances in a pharmaceutical compound. J. Chromatogr. A 1043: 303-315
  16. Calleja, I. et al. (2004). High–performance liquid-chromatographic determination of rifampicin in plasma and tissues. J. Chromatogr. 1031: 289-294.
  17. Gennaro, M.C., et al. (2001) Ion interaction reagent reversed-phase high-performance liquid chromatography determination of anti-tuberculosis drugs and metabolites in biological fluids. J. Chromatogr. B 754: 477-486.
  18. Kanke, M., et al. (1983). Binding of selected drugs to a “treated” inline filter. Am. J. Hosp.Pharm. 40: 1323-1328.
  19. Khue, N. V., and Jung, L. (1985). Study of the retention of child-dose drugs on cellulose ester membranes during inline intravenous filtration. S-T-P Pharma. 1: 201-207.
  20. Boca, M.B., et al. (2005), A validated HPLC method for determining residues of a dual active ingredient anti-malarial drug on manufacturing equipment surfaces. J. Pharm. Biomed.Anal. 37:461-468.
  21. Maddus, M.S. , and Barrierre, S.L. (1980). A review of complications of amphotericin B therapy; recommendations for prevention and management. Drug Intell. Clin. Pharm. 14: 177-181.
  22. Ines, M., et al. (2006). Quantitative determination of gatifloxacin, levofloxacin, lomefloxacin and pefloxacin fluoroquinolonic antibodies in pharmaceutical preparations by high-performance liquid chromatography. J. Pharm.Biomed.Anal. 40: 179-184.
  23. Fantin, M., et al. (2006). Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties. European Journal of Pharmacology 535: 301-309.
  24. McEvoy, G. K. (Ed.) . (1991) American hospital formulary service drug information 91. American Society of Hospital Pharmacists.
  25. Ober, M.D. et al. (2006), Measurement of the Actual Dose of Triamcinolone Acetonide Delivered by Common Techniques of Intravitreal Injection. American Journal of Ophthalmology 142: 597-600.e1.
  26. Lofwall, M. R. ,et al. (2006). Cognitive and Subjective Acute Dose Effects of Intramuscular Ketamine in Healthy Adults. Experimental and Clinical Psychopharmacology 14: 439-449.
  27. Kato, M., et al. (2005) Examination of meningocele induced by the antitumor agent DE-310 in rat fetuses. Reproductive Toxicology 20: 495-502.28. Miles Pharm.
  28. Langer, O., et al. (2003). Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nuclear Medicine and Biology 30: 285-291.
  29. Pavlik, E. J., et al. (198e). Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity. Cancer Chemother. Pharmacol. 11: 8-15.
  30. Pavlik, E.J., et al. (1982) Sensitivity to anticancer agents in vitro: standardizing the cytotoxic response and characterizing the sensitivities of a reference cell line. Gynecol. Oncol. 14: 243-261.
  31. Oradell, N.J., 1991). Physicians’ Desk Reference. 45th edition.
  32. Rusmin, S., et al. (1977). Effect of inline filtration on the potency of drugs administered intravenously. Am.J. Hosp. Pharm. 34: 1071-1074.
  33. Rudaz, S., et al. (2003). Veuthey, Development and validation of a heart-cutting liquid chromatography-mass spectrometry method for the determination of process-related substances in cetirizine tablets. Analytica Chimica Acta 492: 271-282.
  34. Fazio, T.T., et al. (2007) Quantitative determination and sampling of azathioprine residues for cleaning validation in production area. J. Pharm. Biomed,Anal. 43: 1495-1498.
  35. Thompson, D. F., et al. (1984). Effect of inline filtration on pediatric doses of gentamicin and tobramycin. Infusion 8: 31-32.
  36. Tipple, M. et al. (1977). Availability of active amphotericin B after filtration through membrane filters. Am. Rev. Resp.Dis 115: 879-881.

© 2021 Thomson |
Solutions At Work™

LinkedIn